Exclusive-Kimberly-Clark prepares asset sales to win EU nod for Kenvue deal, sources say
Kimberly-Clark is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The European Commission is expected to formally raise its concerns this week. Kimberly-Clark shares rose 2.7% and Kenvue gained 2.3% on the news. The deal, announced in November, would expand Kimberly-Clark's product range to include Kenvue's brands like Listerine, Aveeno, and Neutrogena.
How this was made
The 30-second read
Why it matters
The article provides the first public detail on the concessions being prepared, a key step toward EU clearance.
Market read
The EU antitrust process is the decisive factor for the $40 bn merger; the news could move both stocks sharply.
What to watch
Potential integration challenges and cultural fit between Kimberly‑Clark and Kenvue could affect post‑deal performance.
Background
Kimberly‑Clark announced a $40 bn bid for Kenvue in November 2025. The EU is reviewing the deal for antitrust concerns.
Ticker impact
Kimberly‑Clark is preparing EU antitrust concessions to secure approval for its $40 bn acquisition of Kenvue.
KMB may rally further if concessions are accepted and the deal clears EU review.
The article reports fresh, material information about deal‑closing steps; investors can act now on the likelihood of regulatory clearance.
Market effects
Consumer staples consolidation may pressure peers to consider similar M&A activity.
EU antitrust scrutiny intensifies for large cross‑border consumer‑goods deals.
The $40 bn transaction is one of the biggest M&A moves in the sector this year, influencing global M&A sentiment.
Counterpoint
If EU regulators deem the concessions insufficient, the deal could be blocked, causing a sharp sell‑off.
Key entities
- CompanyKimberly‑Clark
US consumer‑goods maker seeking to acquire Kenvue.
- CompanyKenvue
Owner of Tylenol, Listerine, Aveeno, Neutrogena, targeted by Kimberly‑Clark.
- RegulatorEuropean Commission
EU competition authority reviewing the merger.
